NMRA
Neumora Therapeutics Inc
NASDAQ · Pharmaceuticals
$2.12
+0.16 (+8.16%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 131.86M | 126.94M | 118.45M |
| Net Income | 20.35M | 17.55M | 19.05M |
| EPS | — | — | — |
| Profit Margin | 15.4% | 13.8% | 16.1% |
| Rev Growth | -7.9% | +5.6% | -2.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 34.64M | 37.73M | 39.82M |
| Total Equity | 119.65M | 122.30M | 132.95M |
| D/E Ratio | 0.29 | 0.31 | 0.30 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 29.65M | 29.50M | 31.41M |
| Free Cash Flow | 15.46M | 12.66M | 10.19M |